Entera Bio appoints Haya Taitel to Board of Directors, Class II

Entera Bio Ltd.

Board expanded Class II from one to two directors; Taitel appointed June 4, 2023, term through 2025 annual meeting.
Taitel is Head of Sanofi's Global Transplant Franchise; previously Kadmon CCO (Rezurock launch) and Johnson & Johnson leader.
Board determined Taitel independent under SEC and Nasdaq rules; no material transactions with company.
Taitel to receive standard non-employee director compensation (cash retainers + annual option grants under 2018 plan).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Haya Taitel

Director

ENTXW · Entera Bio Ltd.

Effective: 2023-06-04
Filed: June 7, 2023, 7:59 PM ET

On June 4, 2023, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), expanded Class II of the Board from one to two directors and appointed Ms. Haya Taitel to fill the resulting vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Haya Taitel was appointed as Director at Entera Bio Ltd..

Action: appointed
Role: Director

Exact text from the filing

On June 4, 2023, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), expanded Class II of the Board from one to two directors and appointed Ms. Haya Taitel to fill the resulting vacancy.

View on SEC.gov

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-002176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.